Sotevtamab

Modify Date: 2024-04-07 12:32:20

Sotevtamab structure	Common Name	Sotevtamab
	CAS Number	2411526-47-9	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Sotevtamab

Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research[1][2][3].

Name	Sotevtamab

Description	Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research[1][2][3].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer
In Vitro	Sotevtamab 抑制 PANC-1 胰腺癌细胞的侵袭[3]。
In Vivo	Sotevtamab (10 and 50 mg/kg, i.v.) is well tolerated and shows no signs of toxicity in monkeys[3].
References	[1]. Gilles Tremblay, et al. Abstract 1467: AB-16B5, a therapeutic monoclonal antibody against human clusterin that blocks the epithelial-to-mesenchymal transition. Cancer Res 15 April 2010; 70 (8_Supplement): 1467. [2]. Cristiano Ferrario, et al. Phase 1 first-in-human study of anti-clusterin antibody AB-16B5 in patients with advanced solid malignancies. Cancer Res 1 July 2017; 77 (13_Supplement): CT098. [3]. Gilles B. et al. Pre-clinical evaluation of AB-16B5, a monoclonal antibody specific for tumor-associated sCLU, demonstrates therapeutic potential as an inhibitor of EMT in prostate, pancreatic and lung cancer. Cancer Res 15 April 2011; 71 (8_Supplement): LB–33.

No Any Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Sotevtamab

Use of Sotevtamab

Names

Sotevtamab Biological Activity

Chemical & Physical Properties

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.